Previous 10 | Next 10 |
home / stock / iphyf / iphyf news
Sanofi to exercise one option to license a new ANKET ® program from Innate; After a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization of the program Innate to receive €15m as option exercise payment ...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi SAR443579 induced clinical benefit in patients with R/R A...
Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients. Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET) In...
The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome which have been selected for oral presentation at the American Society of Hematology (ASH) Annual Meeting Virtual K...
2023-11-14 17:56:04 ET Innate Pharma S.A. (IPHA) Q3 2023 Earnings Conference Call November 14, 2023, 08:00 AM ET Company Participants Henry Wheeler - VP, IR and Communication Mondher Mahjoubi - CEO Sonia Quaratino - Chief Medical Officer Yannis Morel - EVP, B...
Positive final results of lacutamab TELLOMAK Phase 2 trial in S é zary syndrome selected for oral presentation and preliminary data in Peripheral T Cell lymphoma to be displayed in a poster at ASH Annual Meeting 2023 ASH presentation on SAR443579/IPH6101, a potential first-in...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third q...
Positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome selected for oral presentation Preliminary monotherapy lacutamab Phase 1b clinical data and pre-clinical combinability data in patients with per...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. Jefferies London Healthcare Co...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2024 financial calendar: March 21, 2024: Publication of 2023 financial statements May 14, 2024: Publication of revenue for 1Q2024 May 23, 2024:...
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL...